• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Eli Lilly Could Rally After Passing the Test

Successful tests of a rising 200-day moving average line can be great entry points for longs.
By BRUCE KAMICH
Sep 22, 2020 | 09:30 AM EDT
Stocks quotes in this article: LLY, AMGN

In his first "Executive Decision" segment of Mad Money Monday evening, Jim Cramer spoke with David Ricks, chairman and CEO of Eli Lilly & Co. (LLY) , the drug maker whose shares fell 1.9% Monday, along with the broader markets, despite posting positive clinical trial data on the company's breast cancer therapy.

Ricks explained that Lilly's treatment, when added to the current standard of care, has shown to reduce the rate of breast cancer recurrence by 25%. He called the data "great news" for patients and their families, and called it the first significant advancement in almost 20 years.  

Ricks also commented on the company's recent work creating neutralizing antibodies to treat Covid-19 patients. He said in just six months' time, they've gone from nothing to clinical trial data showing they can reduce hospitalization rates by as much as 72%. He said they continue to test their antibodies at hard-hit nursing homes and have partnered with Amgen Inc. (AMGN) to help with manufacturing. 

Doctors love to look at charts so let's check out the price charts of LLY. 
 
In the daily bar chart of LLY, below, we can see that the shares have trended higher the past 12 months. Prices corrected lower in July and August and have tested the rising 200-day moving average line this month. A recent upside bounce tested the underside of the declining 50-day moving average line. Strength Tuesday could put prices above the 50-day line by the close.
 
Trading volume and the On-Balance-Volume (OBV) line declined with prices in July and August but the OBV line has turned upward in recent days. A rising OBV line only happens when traders become more aggressive buyers and volume is heavier on days when the stock closes higher.
 
The trend-following Moving Average Convergence Divergence (MACD) oscillator has turned upward for a cover shorts buy signal and is not far from crossing the zero line for an outright buy signal. 
 
 
In the weekly bar chart of LLY, below, we can see that prices are holding above the rising 40-week moving average line.
 
The weekly OBV line looks like it is curving upward from August and the MACD oscillator has been narrowing toward a bullish crossover above the zero line. 
 
 
In this daily Point and Figure chart of LLY, below, we can see that the chart suggests the $139 area as a possible downside price objective. Note that a rally to $155.50 or higher will probably turn the chart bullish. 
 
 
In this weekly close-only Point and Figure chart of LLY, below, we can see a potential price target in the $208 area. 
 
 
 
Bottom-line strategy: Successful tests of a rising 200-day moving average line can be great entry points for longs. Traders could long LLY or add to longs at current levels risking a close below $145 or below the 200-day moving average line. Our price target for now is $200.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Healthcare | Pharmaceuticals | Mad Money | Executive Interview

More from Stocks

Traders: Keep Your Fingers on the Trigger and Targets on a Bottom

James "Rev Shark" DePorre
Mar 4, 2021 4:39 PM EST

As the correction goes on, here's what to do now.

There's Nothing Pleasant About the Current Action

Timothy Collins
Mar 4, 2021 3:00 PM EST

The next good sized bounce in SPAC names, and maybe ARKK names, might be the last exit off the bagholder highway.

Nike's Charts and Indicators Are Still Bearish

Bruce Kamich
Mar 4, 2021 2:20 PM EST

Avoid the long side.

Listen to Mr. Market, Not Mr. Powell

Jim Collins
Mar 4, 2021 1:56 PM EST

Let's look at bonds, rates and, especially, inflation for a true picture of what's going on, and where to put your money.

Powell Supplies the Bears With Ammunition

James "Rev Shark" DePorre
Mar 4, 2021 1:20 PM EST

Picking good stocks is not going to help you much in this market right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:53 AM EST GARY BERMAN

    Nasdaq Composite: Some Backing and Filling Is Here

    As today is the 4th day of the month, it seems lik...
  • 07:59 AM EST PAUL PRICE

    Fabulous News on United Natural Foods (UNFI)

    The major potential risk factor for , its contrac...
  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login